Drug intelligence / Profile preview

3-(6-hydroxynaphthalen-2-yl)-1,2-benzoxazol-6-ol

Development stage: Unknown
Modality: Small Molecules

Overview

3-(6-hydroxynaphthalen-2-yl)-1,2-benzoxazol-6-ol is a synthetic small molecule belonging to the class of naphthol derivatives. It has been cataloged in chemical and drug databases (e.g., DrugBank DB07236 and ChEMBL187105) as an experimental compound. There are no approved medical indications or marketed formulations for this molecule. Its mechanism of action and biological targets have not been definitively established in the public domain; however, it has been included in binding affinity studies and bioassays suggesting potential pharmacological activity[1][7][10]. No clinical trials or therapeutic uses are reported.

Other names: 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL3-(6-hydroxynaphthalen-2-yl)-benzo[d]isoxazol-6-ol

Beyond the preview

Go deeper on 3-(6-hydroxynaphthalen-2-yl)-1,2-benzoxazol-6-ol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-(6-hydroxynaphthalen-2-yl)-1,2-benzoxazol-6-ol.

Explore the full profile